| Peter G Amann, MD | |
|
96 Campus Dr, Suite 2c, Scarborough, ME 04074-7133 | |
| (207) 883-7926 | |
| (207) 883-1925 |
| Full Name | Peter G Amann |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 96 Campus Dr, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639107840 | NPI | - | NPPES |
| 299710099 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD15880 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467477349 PECOS PAC ID: 9335043967 Enrollment ID: O20031125000026 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639194509 PECOS PAC ID: 7517860588 Enrollment ID: O20040206000472 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598780447 PECOS PAC ID: 9335043967 Enrollment ID: O20040220000847 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073527388 PECOS PAC ID: 9335043967 Enrollment ID: O20050401000844 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter G Amann, MD 301c Us Route 1, Scarborough, ME 04074-9701 Ph: (207) 396-8600 | Peter G Amann, MD 96 Campus Dr, Suite 2c, Scarborough, ME 04074-7133 Ph: (207) 883-7926 |
News Archive
A $17.9 million(AUD) refurbishment and extension to ANSTO's radiopharmaceuticals production facility will commence following a special sod-turning by the Federal Minister for Science, Mr Peter McGauran, next week.
Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers at Trinity College Dublin's School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.
› Verified 9 days ago
Mr. Gavin M Ducker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Professional Dr Ste 2c, Scarborough, ME 04074 Phone: 207-883-7926 | |
Mrs. Kristyn Michelle Kee, FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 96 Campus Dr, Scarborough, ME 04074 Phone: 603-303-0108 | |
Kristen Alyse Scopaz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Mussey Rd, Scarborough, ME 04074 Phone: 207-885-1333 Fax: 207-885-1332 | |
Gwendolyn Oguin, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 20 Mussey Rd, Suite 2, Scarborough, ME 04074 Phone: 207-885-1333 Fax: 207-885-1337 | |
Dr. David Merrill, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 69 Us Route 1, 6 Nonesuch Rd, Scarborough, ME 04074 Phone: 207-883-8100 | |
Felicia Jo Munster, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Campus Dr, Scarborough, ME 04074 Phone: 207-396-7683 Fax: 207-396-7684 | |
Dr. Howard Manning Chase, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 438 Us Route 1, Scarborough, ME 04074 Phone: 207-883-4124 Fax: 207-883-0732 |